Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.32 |
| ▸ | GRM8 | O00222 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15509381 | 1.00 | GSTP1 (0.41) | GSTP1L3MBTL1MAPTCYP2D6NFKB1 | |
| SCHEMBL1661418 | 0.87 | SLC1A1 (0.48) | GSTP1L3MBTL1MAPTCYP2D6NFKB1 | |
| SCHEMBL3289233 | 0.87 | SLC1A1 (0.48) | GSTP1L3MBTL1MAPTCYP2D6NFKB1 | |
| SCHEMBL28063444 | 0.86 | GSTP1 (0.38) | GSTP1L3MBTL1MAPTCYP2D6NFKB1 | |
| SCHEMBL29206591 | 0.85 | CYP2D6 (0.55) | MAPTCYP2D6NFKB1LMNASLC1A1 | |
| SCHEMBL29206598 | 0.85 | CYP2D6 (0.55) | MAPTCYP2D6NFKB1LMNASLC1A1 | |
| SCHEMBL21590074 | 0.79 | SLC1A3 (0.38) | MAPTCYP2D6NFKB1LMNASLC1A1 | |
| SCHEMBL21590082 | 0.79 | SLC1A3 (0.38) | MAPTCYP2D6NFKB1LMNASLC1A1 | |
| SCHEMBL10011969 | 0.78 | GSTP1 (0.41) | GSTP1L3MBTL1MAPTCYP2D6NFKB1 | |
| SCHEMBL13314437 | 0.78 | GSR (0.42) | GSTP1SLC1A1SLC1A3SLC1A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118001458-A | In-situ electrical stimulation nerve conduit based on polyamino acid electrode material | 中国科学院长春应用化学研究所 | 2024-05-10 | — | — | CN | disclosed |
| EP-2704246-B1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTRICAL STORAGE DEVICE UTILIZING SAME, AND CYCLIC SULFONIC ACID ESTER COMPOUND | UBE INDUSTRIES (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-9608287-B2 | Non-aqueous electrolytic solution, electrical storage device utilizing same, and cyclic sulfonic acid ester compound | UBE INDUSTRIES, LTD. (JP) | 2017-03-28 | — | — | US | disclosed |
| EP-2704246-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTRICAL STORAGE DEVICE UTILIZING SAME, AND CYCLIC SULFONIC ACID ESTER COMPOUND | Ube Industries, Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| EP-2493868-A2 | POLY(PROPARGYL-L-GLUTAMATE) AND DERIVATIVES THEREOF | Massachusetts Institute Of Technology (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8222359-B2 | Poly(propargyl-L-glutamate) and derivatives thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2011056645-A2 | POLY(PROPARGYL-L-GLUTAMATE) AND DERIVATIVES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110097419-A1 | Poly(Propargyl-L-Glutamate) and Derivatives Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097419-A1 | Poly(Propargyl-L-Glutamate) and Derivatives Thereof | GLUL, QPCTL, QPCT | GSTP1 1608/4885L3MBTL1 2871/4885MAPT 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.